Novartis is paying China’s Abogen Biosciences $575 million (€512 million) upfront for global rights to ABO2203, an ...
Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results